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Summary: Numerous studies have shown that the major
risk factors for coronary heart disease (cigarette smoking,
hypertension, elevated serum total cholesterol and low-den-
sity lipoprotein cholesterol – LDL, low serum high-density
lipoprotein cholesterol – HDL, diabetes mellitus and advan-
cing age), are additive in predictive power. Accordingly, the
total risk of a person can be estimated by summing up the
risk imparted by each of the major risk factors. Using data
obtained from population studies, various risk assessment
algorithms have been developed. The aim of this study was
to compare the two most common risk scores. Risk assess-
ment for determining 10-year risk in 185 healthy, asympto-
matic individuals of both sexes, 30–85 years old, was carried
out according to both Framingham (FRS) and SCORE risk
scoring. The risk factors included in the calculation of 10-year
risk are gender, age, total cholesterol, HDL-cholesterol, sys-
tolic blood pressure, treatment for hypertension and ciga-
rette smoking. The determinations of total cholesterol and
HDL-cholesterol were made in sera collected after a 12h
fasting period using an Olympus AU2700 automated analy-
zer. The Framingham risk score was determined using an
electronic calculator – ATP III Risk Estimator, and the risk sta-
tus according to SCORE was obtained using charts for the
10-year risk in populations at high risk. Among 185 partici-
pants, in 152 (82%) 10-year risk for Coronary Heart Disease
(CHD) death was <10%, 24 (13%) had intermediate and 9
(5%) had high risk (≥20%) according to FRS. According to
SCORE, 110 (60%) participants had <1%, 56 (30%) had
1–5% and 19 (10%) had ≥5% of 10-year risk for cardiovas-
cular death. Different categories of risk were assigned to
∼30% of individuals according to different risk assessment
models. Differences in risk classification when using two dif-
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Kratak sadr`aj: Brojne studije su pokazale aditivnu pre-
diktivnu vrednost glavnih faktora rizika za pojavu koronarne
sr~ane bolesti (pu{enje, hipertenzija, povi{ena koncentraci-
ja ukupnog i LDL-holesterola i niska koncentracija HDL-ho-
lesterola u serumu, dijabetes i starost). Na osnovu toga,
ukupan rizik za jednu osobu mo`e se proceniti sumiranjem
rizika koji nosi svaki glavni faktor rizika pojedina~no. Veliki
broj algoritama za procenu rizika razvijen je na osnovu po-
dataka dobijenih iz populacionih studija. Cilj ovog rada bio
je pore|enje dva naj~e{}e kori{}ena rizik skora. Za 185
zdravih, asimptomatskih osoba oba pola, 30–85 godina sta-
rosti, procenjen je rizik od pojave kardiovaskularnih bolesti
(KVB) u narednih 10 godina prema »Framingham« (FRS) i
SCORE sistemu. Faktori rizika koji su uklju~eni u izra~una-
vanje 10-godi{njeg rizika su pol, starost, ukupan i HDL-
holesterol, sistolni krvni pritisak, terapija antihipertenzivima
i pu{enje. Ukupan i HDL-holesterol odre|ivani su u uzorci-
ma seruma, dobijenim posle 12 sati gladovanja, na biohemij-
skom analizatoru Olympus AU2700. FRS je izra~unavan
pomo}u programa »ATP III Risk Estimator«, a SCORE rizik
je dobijen pomo}u tablica za 10-godi{nji rizik za populacije
sa visokim rizikom. Od 185 u~esnika, kod 152 (82%) 10-
godi{nji rizik za sr~anu smrt bio je <10%, 24 (13%) je ima-
lo srednji, a 9 (5%) je imalo visoki rizik (≥20%) na osnovu
FRS. Prema SCORE-u, 110 u~esnika (60%) imalo je 10-
godi{nji rizik od kardiovaskularne smrti <1%, 56 (30%) je
imalo 1–5% rizika, dok je kod 19 osoba (10%) identifikovan
visok rizik (≥5%). Oko 30% ispitanika svrstano je u razli~ite
kategorije rizika na osnovu razli~itih modela za procenu
rizika. Razlike u klasifikaciji na osnovu kardiovaskularnog
rizika, koje se dobijaju kori{}enjem dva razli~ita algoritma
za procenu rizika, mogu se objasniti time {to ovi sistemi
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Introduction
Cardiovascular disease (CVD) is generally due to
a combination of several risk factors. Numerous stu-
dies have shown that the major and independent risk
factors for coronary heart disease (CHD) are cigarette
smoking of any amount, hypertension, elevated se-
rum total cholesterol and low-density lipoprotein cho-
lesterol – LDL, low serum high-density lipoprotein
cholesterol – HDL, diabetes mellitus and advancing
age (1, 2). These studies (3) show that the major risk
factors are additive in predictive power. Accordingly,
the total risk of a person can be estimated by sum-
ming up the risk imparted by each of the major risk
factors. 
At least 25% of coronary patients experience
sudden cardiac death or nonfatal myocardial infarc-
tion without prior symptoms (3). Therefore, identifi-
cation of coronary patients with subclinical disease,
who could potentially benefit from intensive primary
prevention efforts, is critically important. CHD events
can be predicted with multivariate equations deve-
loped using data from large population studies (4, 5,
6), in which major risk factors are variables. However,
none of these risk assessment models is considered
ideal, but they are essential to begin the process of
selecting patients for further intervention or additio-
nal testing. 
The most frequently used risk assessment algo-
rithm is the Framingham Risk Score (FRS) (4, 7). It is
incorporated in the Adult Treatment Panel III (ATP III)
(8), clinical guidelines recommended by the American
Heart Association (AHA) and the American College of
Cardiology (ACA) for cholesterol testing and manage-
ment. Risk factors used in Framingham scoring include
age, sex, total cholesterol, HDL, systolic blood pressure
(regardless of whether the person is on antihypertensive
therapy) and smoking status. The score is derived from
the Framingham community cohort of 5345 individuals
followed-up for 12 years. Endpoints of the follow-up
were death due to CHD, myocardial infarction, angina
or coronary insufficiency. Framingham scoring divides
persons with multiple risk factors into those with high,
intermediate and low 10-year risk for CHD of >20%,
10 – 20% and <10%, respectively. 
European guidelines on CVD prevention in cli-
nical practice (9) recommend using the SCORE Mo-
del (Systemic COronary Risk Evaluation) (10) to
assess the risk for development of CVD. The SCORE
Project Group analysed over 200 000 individuals from
11 European countries, followed-up for a mean of 13
years for cardiovascular death. In SCORE, the follo-
wing risk factors are integrated: gender, age, smo-
king, systolic blood pressure and either total choles-
terol or the total cholesterol/HDL ratio. Since it pre-
dicts fatal events, the threshold for high risk is defined
as ≥5%. SCORE Project developed separate algo-
rithms for high-risk and low-risk populations.
The aim of this study was to compare CVD risk
determined by using both FRS and SCORE scoring
systems.
Patients and Methods
Participants in this study were 185 healthy
asymptomatic individuals, 59 men and 126 women,
30–85 years of age. Blood samples were collected
after a 12h fasting period. Prior to sample collection,
the volunteers were interviewed about their age,
smoking status and whether they used antihyperten-
sive drugs. Also, their blood pressure was measured.
Persons who had smoked in any amount in the past
month were designated as »smokers«. 
Total cholesterol and HDL concentrations were
measured in fresh serum samples. Both determina-
tions were performed on an Olympus AU2700 auto-
mated analyzer (Olympus Diagnostica GmbH, Ham-
burg, Germany). Total cholesterol was determined by
an enzymatic, and HDL using a direct method.
FRS was determined using an electronic calcu-
lator – ATP III Risk Estimator (version 2000, Ralph B.
D’Agostino, Lisa M. Sullivan, Daniel Levy; Framing-
ham Heart Study) (11). Risk status according to
SCORE was obtained using high risk charts (9, 10),
since CHD rate in the Serbian population is high.
Results
Obtained values of determined parameters for the
studied group of volunteers are presented in Table I.
Among 185 participants, in 152 (82%) the
10-year risk for myocardial infarction and coronary
ferent risk assessment algorithms can be explained with sev-
eral important issues, including different endpoints, consid-
eration of interactions and incorporation of antihypertensive
use. It is important to note that neither FRS nor SCORE have
been appropriately adjusted for our population, according to
the national cardiovascular mortality rate.
Keywords: cardiovascular disease, risk assessment, Fra-
mingham Risk Score, SCORE
koriste razli~ite krajnje ishode bolesti i {to se razlikuju po
uticaju interakcija i uzimanju u obzir upotrebe antihiperten-
zivnih lekova. Va`no je naglasiti da ni FRS ni SCORE nisu
prilago|eni na{oj populaciji, na osnovu nacionalne stope
mortaliteta od KVB.
Klju~ne re~i: kardiovaskularna bolest, procena rizika, »Fra-
mingham« rizik skor, SCORE
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death was <10%, 24 (13%) had intermediate
(10–20%) CHD risk and 9 (5%) were identified as per-
sons with high risk (FRS ≥20%). According to SCORE,
110 (60%) participants had <1%, 56 (30%) had 1–5%
and 19 (10%) had ≥5% of 10-year risk for cardiovas-
cular death. These data are represented in Figure 1.
Different categories of risk were assigned to 56
(∼30%) individuals according to different risk assess-
ment models. Fifty of them (27%) had a risk that diffe-
red by one risk category and the other 6 (3%) were de-
signated as belonging to both the lowest and highest
risk class depending on the used risk algorithm. Higher
risk according to the SCORE system had 28% of parti-
cipants, and according to FRS only 2%.
We also used both SCORE risk charts: one ba-
sed on total cholesterol and the other on choleste-
rol/HDL ratio. The same estimated risk using both
methods had 94% of persons. However, for 11 parti-
cipants (6%), on 10-year risk was different, depen-
ding which variable was used for calculation. 
Discussion
Use of risk scores can provide a reliable risk esti-
mate, leading to more aggessive care and a potential
reduction in vascular disease events. There are various
risk assessment algorithms available, of which the
American FRS and the European SCORE are most
commonly used. Differences in CVD risk classification
when using these two different models can be explai-
ned with several important issues. These include diffe-
rent endpoints, consideration of interactions and incor-
poration of the use of antihypertensive drugs (12). 
Firstly, SCORE is aimed at the estimation of total
cardiovascular risk, rather than the risk of coronary
heart disease incorporated in FRS. This means that
SCORE predicts any kind of fatal atherosclerosis end-
point over a ten-year period. The risk of cardiovascular
death is calculated by combining two separate risk esti-
mations: a model for CHD and a model for all non-
coronary atherosclerotic CVD. Since this model pre-
dicts fatal events, the threshold for being at high risk is
defined as ≥5%, instead of the previous 20%, in charts
using a composite coronary end point (5, 9). 
A prominent feature of risk estimation by means
of the FRS is the progressive increase in absolute risk
with advancing age. This increase reflects the cumu-
lative nature of atherogenesis, but it may mask the
extent of variability in risk because of different plaque
burden in older individuals (3). To avoid this disad-
vantage, SCORE is using age as a measure of expo-
sure time to risk, rather than as a risk factor (10). How-
ever, since age is a major determinant of coronary
risk, SCORE has limited calculation of the model, fit
for the age group 45–65. On the other hand, FRS
evaluation is possible for the age 30–80.
Although SCORE Project Group reported that
there was no consistent indication of the superiority of
cholesterol/HDL ratio-based over cholesterol-based
charts (10), leaving out the HDL may be considered as
a limitation (7). Our results showed some discrepan-
cies among 10-year risks obtained using the two mo-
dels. These differences were observed mainly in per-
sons with very low or very high HDL levels. In these
cases, individuals would have been classified in a
higher or lower risk category, respectively, when the
cholesterol/HDL-based chart was used.
For estimating the 10-year risk for developing
CHD using FRS, blood pressure value obtained at the
time of assessment is used, regardless of whether the
person is on antihypertensive treatment. However, if
the person is on antihypertensive treatment, an extra
point is added beyond points for the blood pressure
reading, because treated hypertension carries resi-
dual risk (8). 
Finally, we must emphasize that neither FRS nor
SCORE have been appropriately adjusted for our po-
pulation. Although FRS has been successfully exter-
nally validated (13), it seems that it overestimates the
Men Women 
n 59 126
Age (year) 45.2 (14.3) 42.8 (12.5)
Smokers (%) 44 17
Systolic blood pressure (mmHg) 129 (15) 120 (18)
Blood pressure medication (%) 16 46
Serum total cholesterol
(mmol/L)
5.83 (1.26) 5.53 (1.24)
Serum HDL cholesterol
(mmol/L)
1.29 (0.89) 1.53 (0.35)
Total cholesterol/HDL 5.5 (2.2) 3.8 (1.2)
Table I Characteristics of the studied group of volunteers.
Figure 1 The distribution of risk in examined group of vo-
lunteers according to FRS and SCORE. 
FRS: <10% low, 10–20% intermediate, ≥20% high risk.
SCORE: <1% low, 1–5% intermediate, ≥5% high risk.
Values are presented as mean (SD) or proportions.
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absolute risk in populations with lower CHD rates. An
important advantage of SCORE is that it is calibrated
to baseline risk within geographical regions, taking
into account genetic and environmental factors,
which allowed the development of separate risk
charts for high-risk and low-risk European popula-
tions. Also, SCORE is open to creating national and
regional risk charts based on the published mortality
data (10).
Since Serbian Medical Society has accepted the
individual risk evaluation based on SCORE charts (14),
we hope that adjustments according to our national
cardiovascular mortality rate will soon be made.
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